Erasca Net Income Over Time
| ERAS Stock | USD 10.13 0.37 3.52% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Erasca Performance and Erasca Correlation. Is there potential for Biotechnology market expansion? Will Erasca introduce new products? Factors like these will boost the valuation of Erasca. Projected growth potential of Erasca fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about Erasca listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Erasca Inc is measured differently than its book value, which is the value of Erasca that is recorded on the company's balance sheet. Investors also form their own opinion of Erasca's value that differs from its market value or its book value, called intrinsic value, which is Erasca's true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Erasca's market value can be influenced by many factors that don't directly affect Erasca's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Erasca's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Erasca should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Erasca's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Net Income Analysis
Compare Erasca Inc and related stocks such as Astria Therapeutics, ArriVent BioPharma Common, and MoonLake Immunotherapeuti Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ATXS | (15.7 K) | (15.7 K) | (15.7 K) | (18.1 M) | (21.9 M) | (32.6 M) | (36.1 M) | (27.4 M) | (25.9 M) | (26.3 M) | (37.1 M) | (194.9 M) | (50.2 M) | (72.9 M) | (94.3 M) | (84.8 M) | (80.6 M) |
| AVBP | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (36.9 M) | (69.3 M) | (80.5 M) | (80.5 M) | (72.4 M) | (76.1 M) |
| MLTX | (90.8 K) | (90.8 K) | (90.8 K) | (90.8 K) | (90.8 K) | (90.8 K) | (90.8 K) | (90.8 K) | (90.8 K) | (90.8 K) | (90.8 K) | (4.5 M) | (64.5 M) | (36 M) | (118.9 M) | (107 M) | (101.7 M) |
| IOVA | (57.1 K) | (25.7 M) | (3.3 M) | (25.4 M) | (12 M) | (27.7 M) | (52.9 M) | (92.1 M) | (123.6 M) | (187.1 M) | (259.6 M) | (327.8 M) | (389.9 M) | (444 M) | (372.2 M) | (335 M) | (318.2 M) |
| MGTX | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (31 M) | (82.9 M) | (54.7 M) | (58 M) | (79.6 M) | (129.6 M) | (84 M) | (147.8 M) | (133 M) | (126.4 M) |
| MBX | (26.1 M) | (26.1 M) | (26.1 M) | (26.1 M) | (26.1 M) | (26.1 M) | (26.1 M) | (26.1 M) | (26.1 M) | (26.1 M) | (26.1 M) | (26.1 M) | (26.1 M) | (32.6 M) | (61.9 M) | (55.7 M) | (58.5 M) |
| CTMX | (15.1 M) | (15.1 M) | (15.1 M) | (15.1 M) | (30.3 M) | (35.4 M) | (58.9 M) | (43.1 M) | (84.6 M) | (102.2 M) | (64.8 M) | (80.6 M) | (97.3 M) | (569 K) | 31.9 M | 36.6 M | 38.5 M |
| CRVS | (176 K) | (176 K) | (176 K) | (176 K) | (176 K) | (31.3 M) | (36.4 M) | (55.7 M) | (46.9 M) | (43.7 M) | (4.8 M) | (43.2 M) | (41.3 M) | (27 M) | (62.3 M) | (56.1 M) | (58.9 M) |
| ARVN | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (24 M) | (41.5 M) | (62.1 M) | (111.8 M) | (183.2 M) | (271.9 M) | (367.3 M) | (198.9 M) | (179 M) | (188 M) |
| VALN | (1.2 M) | (4.4 M) | (14.8 M) | (24.1 M) | (26.3 M) | (20.6 M) | (49.2 M) | (11.5 M) | 3.3 M | (1.7 M) | (64.4 M) | (73.4 M) | (143.3 M) | (101.4 M) | (12.2 M) | (11 M) | (11.6 M) |
Erasca Inc and related stocks such as Astria Therapeutics, ArriVent BioPharma Common, and MoonLake Immunotherapeuti Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Erasca Inc financial statement analysis. It represents the amount of money remaining after all of Erasca Inc operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Erasca Inc | ERAS |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 3115 Merryfield Row, |
| Exchange | NASDAQ Exchange |
USD 10.13
Additional Tools for Erasca Stock Analysis
When running Erasca's price analysis, check to measure Erasca's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Erasca is operating at the current time. Most of Erasca's value examination focuses on studying past and present price action to predict the probability of Erasca's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Erasca's price. Additionally, you may evaluate how the addition of Erasca to your portfolios can decrease your overall portfolio volatility.